Top-News

Telix Pharmaceuticals Aktie (ADR) News

Aktie
WKN:  A40FCQ ISIN:  US87961M1053 US-Symbol:  TLX Branche:  Pharmazeutika Land:  Australien
9,85 $
+0,07 $
+0,72%
8,4594 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
2,69 Mrd. €
Streubesitz
-
KGV
-
Faktor
1
Originalaktie
AU000000TLX2

Telix Pharmaceuticals Aktie (ADR) News

16.08.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX PR Newswire
11.08.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX PR Newswire
06.08.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX PR Newswire
31.07.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX PR Newswire
31.07.25 - PR Newswire
Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman
Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman PR Newswire
27.07.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX PR Newswire
19.07.25 - PR Newswire
Prostatakrebs-PSMA-PET-Bildgebungsmittel Illuccix® in Österreich zugelassen
Prostatakrebs-​PSMA-PET-Bildgebungsmittel Illuccix® in Österreich zugelassen PR Newswire
25.06.25 - PR Newswire
Telix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial Doses
Telix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial Doses PR Newswire
13.06.25 - PR Newswire
Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Greece
Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Greece PR Newswire
11.06.25 - PR Newswire
Telix Illuccix® PSMA-PET-Bildgebungsmittel in Deutschland zugelassen
Telix Illuccix® PSMA-​PET-Bildgebungsmittel in Deutschland zugelassen PR Newswire
05.06.25 - PR Newswire
Telix's Illuccix® PSMA-PET Imaging Agent Approved in Germany
Telix's Illuccix® PSMA-PET Imaging Agent Approved in Germany PR Newswire
04.06.25 - PR Newswire
Telix's Illuccix® PSMA-PET Imaging Agent Approved in Portugal
Telix's Illuccix® PSMA-PET Imaging Agent Approved in Portugal PR Newswire
05.05.25 - PR Newswire
Telix's Illuccix® PSMA-PET Imaging Agent Approved in the Czech Republic
Telix's Illuccix® PSMA-PET Imaging Agent Approved in the Czech Republic PR Newswire
30.04.25 - PR Newswire
Illuccix Prostate Cancer PSMA-PET Imaging Agent Approved in Finland
Illuccix Prostate Cancer PSMA-PET Imaging Agent Approved in Finland PR Newswire
28.04.25 - PR Newswire
Telix's Illuccix PSMA-PET Imaging Agent Approved in France
Telix's Illuccix PSMA-PET Imaging Agent Approved in France PR Newswire
15.04.25 - PR Newswire
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate PR Newswire
15.04.25 - PR Newswire
Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Sweden
Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Sweden PR Newswire
17.03.25 - PR Newswire
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America PR Newswire
12.03.25 - PR Newswire
Telix Adds Lead-212 Isotope Production Capability
Telix Adds Lead-212 Isotope Production Capability PR Newswire
25.02.25 - PR Newswire
FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review
FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review PR Newswire

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »